Home Featured Page 109

Featured

Latest

Op-Ed: Beyond Clinical Trials: Psychedelic-Assisted Therapy in Europe’s Real World

The Psychedelic News Feed: January 12 – 18, 2026

Australia’s Psychedelic Experiment: Progress, Pitfalls, and What Comes Next

Views from the Field on Psychedelics in 2026: Excitement, Anxiety, and Open Questions

Op-Ed: Psychedelics in Practice: What the State Programs Are Teaching Us

PT395 – Thank You Life: Accessibility, Fair Compensation, and Trusting Intuition

COMPASS Pathways to participate in upcoming Cowen 43rd Annual Health Care...

GH Research Reports Full Year 2022 Financial Results and Provides Business...

Algernon NeuroScience Appoints Global TBI Expert and Former NFL Neurological Player...

atai Life Sciences to Participate in the Cowen 43rd Annual Health...

Mycoprenuer Podcast – Joe Moore & Kyle Buller: Psychedelics Today

Psychedelic Health – Psychedelics Today: improving access to psychedelic therapy training

Small Pharma to Present at Cowen’s 43rd Annual Health Care Conference

Optimi Health Enters Australian Medical MDMA And Psilocybin Market With Mind...

1...108109110...306 Page 109 of 306

Op-Ed: Beyond Clinical Trials: Psychedelic-Assisted Therapy in Europe’s Real World

The Psychedelic News Feed: January 12 – 18, 2026

Australia’s Psychedelic Experiment: Progress, Pitfalls, and What Comes Next

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Op-Ed: Beyond Clinical Trials: Psychedelic-Assisted Therapy in Europe’s Real World

The Psychedelic News Feed: January 12 – 18, 2026

Australia’s Psychedelic Experiment: Progress, Pitfalls, and What Comes Next

Views from the Field on Psychedelics in 2026: Excitement, Anxiety, and Open Questions

Op-Ed: Psychedelics in Practice: What the State Programs Are Teaching Us

PT395 – Thank You Life: Accessibility, Fair Compensation, and Trusting Intuition

COMPASS Pathways to participate in upcoming Cowen 43rd Annual Health Care...

GH Research Reports Full Year 2022 Financial Results and Provides Business...

Algernon NeuroScience Appoints Global TBI Expert and Former NFL Neurological Player...

atai Life Sciences to Participate in the Cowen 43rd Annual Health...

Mycoprenuer Podcast – Joe Moore & Kyle Buller: Psychedelics Today

Psychedelic Health – Psychedelics Today: improving access to psychedelic therapy training

Small Pharma to Present at Cowen’s 43rd Annual Health Care Conference

Convergence: Canceled

Optimi Health Enters Australian Medical MDMA And Psilocybin Market With Mind...

EDITOR PICKS

Op-Ed: Beyond Clinical Trials: Psychedelic-Assisted Therapy in Europe’s Real World

The Psychedelic News Feed: January 12 – 18, 2026

Australia’s Psychedelic Experiment: Progress, Pitfalls, and What Comes Next

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY